Rupatadine: pharmacological profile and its use in the treatment of allergic disorders.
Rupatadine is a once-daily, non-sedating, selective and long-acting new drug with a strong antagonist activity towards both histamine H(1) receptors and platelet-activating factor receptors. The use of rupatadine is indicated in adult and adolescent patients (> 12 years of age) suffering from intermittent and persistent allergic rhinitis and chronic idiopathic urticaria. In the treatment of these diseases, rupatadine is at least as effective as ebastine, cetirizine, loratadine and desloratadine. A very good safety profile of rupatadine has been evidenced in various studies, including a long-term (1-year) safety study. Rupatadine does not present drug-drug interactions with azithromycin, fluoxetine and lorazepam, but should not be administered concomitantly with known CYP3A4 inhibitors.
Picado
César
C
University of Barcelona, Servei de Pneumologia i Allèrgia Respiratoria, Hospital Clínic, c/Villarroel 170, 08036 Barcelona, Spain. cpicado@ub.edu
D000293:Adolescent; D000328:Adult; D000818:Animals; D003533:Cyproheptadine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D011597:Psychomotor Performance / Q000187:drug effects; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D014581:Urticaria / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; C103639:rupatadine; D003533:Cyproheptadine